THALES
16.3.2021 10:02:09 CET | Business Wire | Press release
Thales announces a new data protection capability for Microsoft customers to benefit from the power of the full range of Microsoft 365 applications while protecting sensitive data in the cloud and meeting major data privacy regulations and requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005009/en/
Designed for companies that operate in highly-regulated sectors such as financial services and healthcare, they can now leverage Thales Luna Hardware Security Modules (HSMs) with Double Key Encryption for Microsoft 365 and comply with regulations such as the EU General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and the recommendations from the European Data Protection Board (EDPR) following the Schrems II ruling.
Securing Data in the Era of Remote Working and Increased Privacy Regulations
Today’s remote working environment relies heavily on the collaborative sharing of information, challenging organisations to maintain the security of confidential data and regulatory compliance while driving employee productivity. For organisations in highly regulated industries such as financial services, governments, and healthcare, their sensitive data requires the highest level of control and security. The integration of Luna HSMs with Double Key Encryption for Microsoft 365 delivers the protection required to protect highly sensitive data and meet unique regulatory requirements.
“The premise of remote working is no longer a perk reserved for a select few, but now the default operating model for many companies,” said Imran Mohiuddin, DKE partner director at Microsoft. “Our collaboration and productivity tools for Microsoft 365 customers are designed to enable companies to thrive in any situation. A key part in enabling this to happen though is ensuring they have the best security and compliance solutions when it comes to protecting sensitive data. Our Double Key Encryption integration with Thales enables customers who have enhanced data protection requirements, compliance obligations and regulatory restrictions to protect their highly sensitive information. By having full control of their encryption keys, customers can be certain that no third-party has access to their unencrypted data -- including Microsoft. Security should never be something that holds companies back in this remote era and from moving their sensitive information to the cloud, and with Thales, we’re ensuring it won’t for our customers.”
Thales has integrated its industry-leading Luna HSMs with Microsoft Double Key Encryption for Microsoft 365. This allows customers to protect their most confidential or sensitive data while maintaining control of their encryption keys in the cloud. The solution works by using two keys to protect data. One key is managed securely by the customer via the Luna HSM and a second key in Microsoft’s control. To view the data, one must have access to both keys, meaning it can’t be used without the customer’s permission.
“Our collaboration with Microsoft is designed to give peace of mind to customers when it comes to security, no matter where or what Microsoft applications they’re accessing,” said Todd Moore, vice president of encryption solutions at Thales. “The way we work has changed forever and in order to thrive, businesses have had to increasingly adapt and adopt collaborative applications. The integration of Thales Luna HSMs with Microsoft Double Key Encryption provides businesses with control over their encrypted data, in line with regulatory requirements, regardless of their industry.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions. Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
|
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005009/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom